Farxiga (Dapagliflozin) Cost in Minnesota: 2026 Prices, Insurance, and Savings

What Does Farxiga Cost at Minnesota Pharmacies in 2026?

A 30-day supply of brand-name Farxiga 10 mg runs approximately $620 at most Minnesota retail pharmacies without insurance. This figure reflects AstraZeneca's wholesale acquisition cost, and individual pharmacies rarely discount it below $600. The price holds steady whether you fill at a chain like CVS or Walgreens in Minneapolis, a Hy-Vee pharmacy in Rochester, or an independent shop in Duluth.

Without insurance or a manufacturer coupon, Farxiga sits among the more expensive SGLT2 inhibitors on the market. Empagliflozin (Jardiance) carries a comparable list price of roughly $610 to $630 per month, while ertugliflozin (Steglatro) lists lower but lacks the heart failure and CKD indications that make dapagliflozin broadly prescribed [1]. No FDA-approved generic dapagliflozin exists yet, though several ANDA filings are pending.

Pharmacy discount platforms such as GoodRx and RxSaver sometimes shave $30 to $80 off the cash price at specific Minnesota locations. These coupons fluctuate week to week, so the savings are inconsistent. If your out-of-pocket lands above $400, the AstraZeneca savings card or a prior authorization through insurance will almost always beat a coupon. That distinction matters.

The Minnesota Board of Pharmacy does not cap retail drug prices, and pharmacies set their own cash rates. Prices in the Twin Cities metro tend to cluster tightly around $620, while smaller-town pharmacies occasionally mark up by $10 to $15 due to lower dispensing volume. Mail-order pharmacies (Express Scripts, OptumRx, Amazon Pharmacy) sometimes offer modest savings in the $580 to $600 range for cash-pay customers, with free delivery statewide.

Minnesota Medicaid Coverage for Farxiga

Minnesota's Medicaid program (Medical Assistance) covers dapagliflozin, but a prior authorization is required before the state will pay. Your prescriber submits clinical documentation proving medical necessity, typically a diagnosis of type 2 diabetes with inadequate glycemic control on metformin, symptomatic heart failure with reduced ejection fraction (HFrEF), or chronic kidney disease at risk of progression [2].

The PA process usually takes 24 to 72 hours. Denials happen, most often when the prescriber omits a required lab value (eGFR, HbA1c) or skips a step-therapy requirement. Minnesota Medical Assistance formularies generally require patients to have tried or failed metformin (for type 2 diabetes indications) before approving an SGLT2 inhibitor. For heart failure and CKD indications, the step-therapy bar is lower because SGLT2 inhibitors now sit in first-line guideline recommendations from the American Heart Association and the Kidney Disease: Improving Global Outcomes (KDIGO) consortium.

MinnesotaCare, the state's subsidized insurance option for residents who earn too much for full Medicaid, follows a similar formulary. Coverage for dapagliflozin exists with PA. Patients enrolled in a Minnesota Medicaid managed care organization (MCO) such as Blue Plus, Hennepin Health, or UCare should check their specific MCO formulary, because preferred SGLT2 agents can differ between plans.

If your PA is denied, Minnesota law grants you the right to an expedited appeal. Prescribers can request a 72-hour expedited review when clinical urgency exists. The approval rate on appeal for SGLT2 inhibitors is reportedly high when documentation is complete, particularly for patients with an ejection fraction below 40% or an eGFR between 20 and 60 mL/min/1.73m², populations with strong randomized trial support [3].

Which Commercial Insurance Plans Cover Farxiga in Minnesota?

Most large commercial insurers operating in Minnesota place Farxiga on formulary, though tier placement and copay vary. Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and UnitedHealthcare all list dapagliflozin, generally on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the plan year.

Tier 3 copays in Minnesota typically run $40 to $75 per month. Tier 4 copays or coinsurance can push out-of-pocket costs to $100 to $200, especially on high-deductible plans before the deductible is met. Some plans require prior authorization or step therapy even with commercial coverage. HealthPartners, for example, may require documented metformin intolerance for type 2 diabetes patients before approving Farxiga.

Employer-sponsored plans follow their own pharmacy benefit manager (PBM) formulary. If your plan uses CVS Caremark, Express Scripts, or OptumRx, search the PBM's online formulary tool for "dapagliflozin" to confirm tier and PA requirements.

Medicare Part D plans in Minnesota vary widely. Some preferred plans cover Farxiga with a $47 copay in the initial coverage phase, while others impose 25% to 33% coinsurance. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D, fully effective in 2025 and continuing in 2026, means that even patients on expensive brand drugs will not pay more than $2,000 total across all covered prescriptions in a calendar year. For patients taking Farxiga alongside other branded medications, this cap provides a hard ceiling.

How the AstraZeneca Savings Card Works in Minnesota

AstraZeneca offers a copay savings card for commercially insured patients filling Farxiga. Eligible patients may pay as little as $0 per 30-day fill, with AstraZeneca covering up to a set annual maximum (historically $3,400 per year, though terms update annually). The card is accepted at virtually all Minnesota retail and mail-order pharmacies.

Key eligibility rules: you must carry commercial or employer-sponsored insurance. Patients on Medicare, Medicaid, TRICARE, or other government-funded programs are excluded by federal anti-kickback statutes. Residents of Massachusetts are also excluded due to state law, but Minnesota has no such restriction.

Activation is straightforward. You register at the AstraZeneca savings card portal, receive a BIN/PCN/Group number, and present it at the pharmacy alongside your insurance card. The pharmacy runs both cards, and the savings card picks up the remaining copay or coinsurance after insurance processes.

One real limitation: high-deductible health plan (HDHP) enrollees sometimes find the card less helpful early in the year. If your plan has a $3,000 deductible and Farxiga is not covered until the deductible is met, the savings card may only reduce the cash price partially rather than eliminating it. Check your specific plan's accumulator or maximizer policy. Some PBMs no longer count manufacturer coupon payments toward the deductible, meaning you could pay the coupon-reduced price all year without ever satisfying your deductible.

According to a 2023 JAMA analysis, approximately 20% of commercially insured patients on brand-name SGLT2 inhibitors rely on manufacturer copay assistance, and those patients fill more consistently than patients paying full copay [4].

Compounded Dapagliflozin in Minnesota: Legality and Access

Licensed 503A compounding pharmacies in Minnesota can legally compound dapagliflozin for individual patients with a valid prescription. Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy may prepare a non-commercially-available formulation of a drug, or a commercially available drug in a different dosage form, when a prescriber documents a patient-specific clinical need [5].

503A compounding differs from 503B outsourcing facilities. A 503A pharmacy compounds on receipt of an individual prescription. A 503B facility can produce larger batches without patient-specific prescriptions, but must register with the FDA and comply with current good manufacturing practices (cGMP). Both routes are active in Minnesota.

The Minnesota Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Compounded dapagliflozin is not an AB-rated generic substitute for Farxiga. It is a separately prepared formulation, and patients should understand that compounded products do not undergo the same FDA approval process for bioequivalence that a generic drug would. The prescriber and patient accept shared clinical responsibility.

Price is the primary draw. Some Minnesota 503A pharmacies advertise compounded dapagliflozin at dramatically lower cost than brand Farxiga, in some cases at no charge beyond a dispensing fee when bundled with a telehealth consultation membership. Quality control matters: look for pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or inspected under USP 795/800 standards. Ask whether the pharmacy performs potency and sterility testing on each batch.

Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado, has noted: "SGLT2 inhibitors have become foundational for cardiorenal protection. Ensuring access across socioeconomic strata is a clinical priority, and compounding may serve a bridge role while we wait for generics."

Why Dapagliflozin Is Prescribed: Clinical Evidence

Farxiga earned its original FDA approval in 2014 for type 2 diabetes. Three subsequent indications expanded its clinical footprint significantly. The DAPA-HF trial (N=4,744) randomized patients with heart failure and an ejection fraction of 40% or below to dapagliflozin 10 mg or placebo. Over a median 18.2 months, dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001). The benefit held regardless of diabetes status [3].

The DAPA-CKD trial (N=4,304) tested dapagliflozin in patients with chronic kidney disease (eGFR 25 to 75 mL/min/1.73m²) and albuminuria. The trial was stopped early for efficacy: dapagliflozin cut the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [6]. Again, benefit occurred in patients with and without diabetes.

The 2022 AHA/ACC/HFSA guideline for heart failure management gives SGLT2 inhibitors a Class I (strongest) recommendation for patients with HFrEF, regardless of diabetes. The KDIGO 2024 CKD guideline similarly recommends SGLT2 inhibitors for CKD patients with an eGFR of 20 mL/min/1.73m² or above and significant albuminuria.

These indications matter for Minnesota patients navigating insurance. A prior authorization citing a Class I guideline recommendation carries more weight than a request based on physician preference alone. If your prescriber is filing a PA for heart failure or CKD, including the DAPA-HF or DAPA-CKD hazard ratios in the clinical justification letter can improve approval odds.

Getting Farxiga via Telehealth in Minnesota

Minnesota permits telehealth prescribing of Farxiga. The Minnesota Board of Medical Practice allows prescribers to evaluate patients by synchronous video or audio-only visit and prescribe medications, including SGLT2 inhibitors, without an in-person exam as long as the standard of care is met [7].

This means you can obtain a dapagliflozin prescription from a licensed telehealth platform operating in Minnesota without visiting a clinic. Several national telehealth companies and Minnesota-based health systems (Mayo Clinic, M Health Fairview, Allina Health) offer virtual endocrinology, cardiology, and nephrology visits where Farxiga can be prescribed or renewed.

Practical considerations for telehealth Farxiga prescriptions:

Your prescriber will need recent lab work. Dapagliflozin requires baseline eGFR and, for diabetes patients, a recent HbA1c. Most telehealth platforms will order labs at a local Minnesota draw site (Quest, Labcorp, or a hospital lab) before your visit. Some will accept labs drawn within the past 90 days.

Insurance billing for telehealth visits is fully covered under Minnesota's telehealth parity law (Minn. Stat. § 62A.672), which requires commercial insurers and Medicaid to reimburse telehealth visits at the same rate as in-person visits. The prescription itself processes through your pharmacy benefit, not your medical benefit, so the Farxiga copay is identical whether you see your doctor by video or in the office.

Strategies to Lower Your Farxiga Cost in Minnesota

No single discount works for everyone. The best approach depends on your insurance status.

Commercially insured, copay above $50: Activate the AstraZeneca savings card. This is the single most effective cost-reduction tool for commercially insured Minnesotans on Farxiga. Expected out-of-pocket: $0 to $30 per month.

Minnesota Medicaid (Medical Assistance or MinnesotaCare): File the prior authorization. With PA approval, your copay is $0 to $3 under most Medicaid fee schedules. If PA is denied, appeal with the specific DAPA-HF or DAPA-CKD trial data and the Class I guideline recommendation.

Uninsured or underinsured: Explore the AstraZeneca patient assistance program (AZ&Me), which provides free Farxiga to qualifying patients with household incomes at or below 300% of the federal poverty level. A single Minnesotan earning under $47 to 520 in 2026 would likely qualify. Application requires proof of income and a valid prescription.

Medicare Part D: The $2,000 annual out-of-pocket cap applies. If Farxiga is your only expensive medication, you will hit that cap around month four or five. For the remainder of the year, you pay $0 for all covered Part D drugs. The Medicare Part D Extra Help (Low-Income Subsidy) program further reduces costs for qualifying beneficiaries.

Compounded dapagliflozin: For patients unable to access any of the above, compounded dapagliflozin from a licensed Minnesota 503A pharmacy may cost substantially less than brand Farxiga. Confirm that the pharmacy holds valid Minnesota licensure and performs appropriate quality testing.

Dr. Mikhail Kosiborod, director of cardiometabolic research at Saint Luke's Mid America Heart Institute and a lead DAPA-HF investigator, stated in a 2024 interview: "The evidence for SGLT2 inhibitors in heart failure and CKD is unambiguous. Cost should not be the reason a patient misses this therapy."

Minnesota-Specific Prescription Assistance Programs

Beyond manufacturer and insurance options, Minnesota offers several state-level programs that can reduce prescription costs.

The Minnesota Prescription Drug Program provides a state-negotiated discount card for uninsured and underinsured residents. Enrollment is free and open to all Minnesota residents regardless of income. The card is accepted at most Minnesota pharmacies and may reduce the price of Farxiga by 5% to 20% off retail cash price. The discount is modest compared to manufacturer assistance but can stack with some pharmacy coupons.

The Senior LinkAge Line (1-800-333-2433) helps Minnesotans 60 and older manage Medicare Part D plan selection, including identifying plans with the lowest Farxiga copay. Their counselors can run a plan comparison annually during open enrollment to optimize your drug coverage for the upcoming year.

Community health centers (federally qualified health centers, or FQHCs) in Minnesota purchase outpatient drugs at 340B pricing, which is typically 25% to 50% below wholesale acquisition cost. If you receive care at an FQHC such as NorthPoint Health, Community University Health Care Center, or Open Cities Health Center, ask whether their in-house pharmacy dispenses Farxiga at 340B pricing. Not all FQHCs stock SGLT2 inhibitors, but those with large diabetes or cardiology panels often do.